List of Personalized Medicine Companies in Canada - 12

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.

BugSeq is an online bioinformatics platform for automated microbiology sequencing analysis. Simply upload your raw data, and our evidence-based pipelines will return actionable reports.COVID-19: (08/2021) SARS-CoV-2 detection with nanopore sequence data.

DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.

StageZero Life Sciences, Inc. is a national clinical reference lab specializing in personalized blood-based testing to find, understand, and provide key information to help guide treatment decisions. Our mission is to provide a comprehensive menu of traditional and advanced clinical evidence-based blood tests that aid in early cancer detection.

Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Our testing services are conducted in our CAP/CLIA/ISO15189-accredited laboratory, where we manufacture IVD and RUO testing kits for in-house solutions. With a global reach, our headquarters are located in both Canada and China. Our products and services are well-established and ordered by over 8,000 long-term oncologist partners across 12+ countries and regions. We are engaged in 2,200+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We work closely with our partners to address their specific needs, maintaining a relentless focus on quality and efficiency.

Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology, dedicated to the highest level of customer satisfaction, quality, and support, maintaining ISO 13485 medical device development and manufacturing standards certification. The Genomadix Cube is a real-time polymerase chain reaction (PCR) molecular diagnostic instrument capable of performing tests for precision medicine genotyping and environmental targets on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform includes tests for: - ​Rapid CYP2C19 Genotyping (FDA 510(k)-Cleared and CE Marked) - Environmental water testing for Legionella pneumophila - Apolipoprotein E (ApoE) RUO genotyping The Cube platform is also available as an open platform called CubeX that can be used to run any qPCR tests for research use only. Genomadix’s technology for the cube includes over 3 million hours of research and development, 11 patents and 30 peer-reviewed scientific publications.

Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules to address hypertriglyceridemia and other metabolic diseases.

The mDETECT tests are highly specific and sensitive blood tests that monitor c tumour burden in cancer (metastatic) patients using targeted methylation marks in circulating tumour DNA (ctDNA). mDETECT can accurately and rapidly determine cancer relapse, progression, and response to therapy to help extend the lives of patients.

Moss is a disrupter in the consumer healthcare space offering personalized health and gut health solutions guided by genomic data, microbiome data, and clinically validated assessments. Founded in 2018, Moss is a technology and healthcare integrator for personalized health and offers a comprehensive line of probiotics and nutritional supplements.

Rna Diagnostics Inc. is a clinical stage molecular diagnostics company for personalized cancer therapy management. We are working with physicians around the globe to improve cancer treatment and the quality of life for patients, while reducing healthcare costs. Our predictive biomarker platform technology, Veridapt DX™, now in clinical trials, is designed to measure early solid tumor response to neoadjuvant cancer treatment. The Veridapt DX predictive biomarker identifies non-responsive solid tumors by monitoring the degree of RNA (rRNA) disruption in the cells. Once validated, the test will enable physicians to escalate or de-escalate therapy, or select an alternative strategy, as early as 5 weeks into a standard 6-month treatment regimen. A series of pre-clinical studies, and retrospective and ongoing prospective clinical data, have shown strong evidence for clinical effectiveness. A large-scale study is now under way to validate Veridapt DX (formerly known as the RNA Disruption Assay) as a tool to manage primary breast cancer treatment: the Breast Cancer Response Evaluation for Individualized Therapy (BREVITY) clinical trial. Phase 1 results, published in JNCI Cancer Spectrum, demonstrate Veridapt DX’s strong capability (Negative Predictive Value >93%) to accurately predict therapy efficacy/outcomes during early treatment. Phase 2 is now under way in 7 countries. Our initial focus is on primary breast cancer; however, our assay platform has the potential to apply to any solid tumor and any cancer drug therapy for personalized, precision medicine. We welcome inquiries from clinicians interested in collaborative trials for early assessment of treatment for solid tumor cancers.

Somru BioScience is an emerging biotechnology company dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications.

STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world. Driven by our love of science and passion for quality, we are Scientists Helping Scientists—standing by our customers to provide the outstanding products, technical support, and training they need to advance their research. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research are among those who rely on our cell culture media, cell separation products, instruments, accessory products, and services. Since the launch of the company by Dr. Allen Eaves in 1993, STEMCELL has reinvested all profits back into the research and development of products to better support the international research community. Today, STEMCELL is the largest biotech company in Canada, with over 2000 employees globally, most with scientific or engineering degrees. Through our many regional offices, as well as our distribution centers in Vancouver, Seattle, Grenoble, and Singapore, we deliver our innovative, specialized products to more than 70 countries. At STEMCELL, we are dedicated to improving lives through advancing knowledge and scientific discovery, through our commitment to fostering diversity and inclusion in STEM and the life sciences industry, and through our investments in sustainability, community, and social responsibility. We do all this because we love science as much as you do. #ScientistsHelpingScientists